ICON plc. (ICLR)

Executive Summary

ICON plc is a leading global clinical research organization (CRO) providing outsourced development and commercialization services to pharmaceutical, biotechnology, and medical device companies. Headquartered in Dublin, Ireland, and publicly traded on NASDAQ under ticker ICLR, ICON has a strong track record in managing complex clinical trials across diverse therapeutic areas. The company’s comprehensive service offerings, including clinical trial management, data analytics, and regulatory support, position it as a key partner for drug development. With over 500 publications and a robust pipeline of completed and ongoing trials, ICON continues to demonstrate its expertise in accelerating time-to-market for innovative therapies. The company’s recent focus on expanding its decentralized trial capabilities and leveraging technology-driven solutions is expected to enhance efficiency and patient recruitment, driving future growth.

Upcoming Catalysts (preview)

• Q4 2026Q3 2026 Earnings Report95% success
• Q3 2026Major Contract Win with Top 20 Pharma55% success
• Q4 2026FDA Approval of Key Client Drug Supported by ICON30% success